News

The active IND now allows the Company to initiate its planned Phase 3 program for ZX008. Zogenix president and CEO Stephen Farr said: "We are pleased to have

The study is being conducted at The University of Texas MD Anderson Cancer Center and is being led by Adi Diab, MD, Assistant Professor, Department of Melanoma Medical

Acute kidney injury (AKI) is a serious medical condition characterized by an abrupt loss of kidney function. AKI is estimated to affect up to 18 percent of hospital

The Wall Street Journal had recently reported that AstraZeneca was looking to acquire Acerta for over $5bn to secure access to its experimental blood cancer drug, acalabrutinib. AstraZeneca

Shopfloor-Online is a well-established, web-based product that has already been installed with hundreds of customers in different sectors across the world and the creation of the Lifescience edition

In the pivotal studies, Alecensa shrank tumors in up to 44 percent of people with ALK-positive NSCLC who progressed on crizotinib (objective response rate [ORR] of 38 percent

The proposed study, which will enroll approximately 75 patients, is projected to launch in Canada in Q2 2016. XBiotech medical director Michael Stecher said, "This program represents the

The candidate, CX-2009, is a first-in-class Probody drug conjugate targeting CD166. CX-2009 utilizes ImmunoGen, Inc. conjugate technology. CytomX chief scientific officer Michael Kavanaugh said: "CD166 is highly and

The collaboration aims to develop new technologies for biologics production and to identify new targets for disease research in the ground-breaking area of the Secretome – research into